C
Cresilon
A medical device company that produces and markets solutions for trauma care
About Cresilon
Cresilon Inc. is a biotechnology company based in Brooklyn, specializing in hemostatic medical device technologies. The company has developed a plant-based adhesive hemostatic gel that can stop traumatic and surgical bleeds in seconds without the need for manual pressure. Cresilon's primary product, VETIGEL, is the first hemostatic gel designed for the veterinary market, offering a rapid and reliable solution to stop bleeding. The company serves clients in the veterinary, human trauma, and surgical markets. Cresilon operates in the medical device sector, focusing on wound care and bleeding control solutions. Its business model involves commercializing its proprietary gel technology through direct sales and partnerships, such as the Preferred Partnership Agreement with VerticalVet, which provides 1,800 veterinary members with access to VETIGEL. Cresilon generates revenue by selling its hemostatic products to veterinary clinics, hospitals, and surgical centers. The company aims to expand its applications for the gel technology to further improve wound care and save lives.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2010
- Headquarters
- New York City, United States
- Employees
- 92
- Open positions
- 4
- Dealroom signal
- 82.2/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VCOther financing | Sep 2025 | $17M | $125M | Undisclosed | ↗ |
| SERIES AOther financing | Oct 2022 | $25M | $100M | Paulson Investment Company | ↗ |
Growth signals
Latest recorded traffic for Cresilon is 10K monthly website visits, up 88.7% over the last three months. Cresilon's team grew 3.4% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
Dorm Room Fund
First Round Capital- HCHammerstone Capital
Series A1 investor entered at this stage
Paulson Investment Company
Other known investors1 additional known investor
New York University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Cresilon on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Cresilon’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.